126 related articles for article (PubMed ID: 10907979)
1. The FDA: protector or puppet?
Terpening CM
Pharmacotherapy; 2000 Jul; 20(7):860-1. PubMed ID: 10907979
[No Abstract] [Full Text] [Related]
2. Drugs and disease.
SoRelle R
Circulation; 2000 Apr; 101(13):E9027-8. PubMed ID: 10747361
[No Abstract] [Full Text] [Related]
3. Plaintiff's attorney actively seeking out patients who have used various FDA approved medications and who "may be entitled to compensation for damages caused by these medications".
South D
J Miss State Med Assoc; 2000 Nov; 41(11):798-9. PubMed ID: 11107716
[No Abstract] [Full Text] [Related]
4. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
5. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
6. From the Food and Drug Administration.
JAMA; 2000 May; 283(17):2228. PubMed ID: 10807369
[No Abstract] [Full Text] [Related]
7. Advisory panel hears contradictory evidence, backs keeping troglitazone on market.
Miller JL
Am J Health Syst Pharm; 1999 May; 56(9):840, 842. PubMed ID: 10344603
[No Abstract] [Full Text] [Related]
8. Update in endocrinology.
Whitcomb RW
Ann Intern Med; 1998 May; 128(10):871. PubMed ID: 9599203
[No Abstract] [Full Text] [Related]
9. Troglitazone withdrawn from market.
Am J Health Syst Pharm; 2000 May; 57(9):834. PubMed ID: 10840515
[No Abstract] [Full Text] [Related]
10. FDA drug-review, surveillance processes under scrutiny.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
[No Abstract] [Full Text] [Related]
11. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
12. The chase is on (and I'm mad as hell).
Ponte CD
J Am Pharm Assoc (Wash); 2000; 40(4):466. PubMed ID: 10932454
[No Abstract] [Full Text] [Related]
13. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone.
Wilkinson JJ; Force RW; Cady PS
Pharmacotherapy; 2004 Aug; 24(8):978-86. PubMed ID: 15338846
[TBL] [Abstract][Full Text] [Related]
14. Diabetes drug withdrawn after reports of hepatic events.
Wise J
BMJ; 1997 Dec; 315(7122):1564. PubMed ID: 9437272
[No Abstract] [Full Text] [Related]
15. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
16. Liver enzyme monitoring in patients treated with troglitazone.
Graham DJ; Drinkard CR; Shatin D; Tsong Y; Burgess MJ
JAMA; 2001 Aug; 286(7):831-3. PubMed ID: 11497537
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone-associated hepatic failure.
Misbin RI
Ann Intern Med; 1999 Feb; 130(4 Pt 1):330. PubMed ID: 10068399
[No Abstract] [Full Text] [Related]
18. Rezulin pulled in the UK.
Zurlinden J
Nurs Spectr (Wash D C); 1998 May; 8(9):25. PubMed ID: 10542729
[No Abstract] [Full Text] [Related]
19. From the Food and Drug Administration.
Nightingale SL
JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135
[No Abstract] [Full Text] [Related]
20. A drug interaction between troglitazone and simvastatin.
Lin JC; Ito MK
Diabetes Care; 1999 Dec; 22(12):2104-6. PubMed ID: 10587866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
